Vodafone to sell NZ business to Infratil Brookfield in US$2.36B deal
Category: #business  By Mateen Dalal  Date: 2019-05-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vodafone to sell NZ business to Infratil Brookfield in US$2.36B deal

Vodafone is seeking to consolidate its businesses in New Zealand and Australia

It had tried to sell Vodafone NZ to satellite TV provider Sky Network in 2017

Reports confirm that Vodafone Group Plc, the British multinational telecommunications conglomerate, has recently agreed to sell its New Zealand business to a consortium comprising of Canada's Brookfield Asset Management and Infratil Ltd, a New Zealand-based infrastructure investment company, for around 2.1 billion euros (US$2.36 billion).

Sources familiar with the matter commented that Vodafone is seeking to consolidate its businesses in New Zealand and Australia, with a total $11 billion worth agreement underway to amalgamate its Australian joint venture business with TPG Telecom. Antitrust regulator of Australia has already blocked that merger bid.

Sources further informed that Deutsche Craigs Limited and Deutsche Bank are acting as a financial consultant to Vodafone.

Apparently, in 2017, Vodafone had attempted to sell Vodafone NZ to NZ television satellite TV provider, Sky Network Television for a total amount of NZ$3.44 billion but did not get regulatory consent due to monopoly concerns.

Vodafone NZ’s newly appointed Chief Executive Officer, Jason Paris had stated in 2018 that it would seek to go public in 2020. In May 2019, Infratil had mentioned that it was in discussions with Vodafone to acquire the its New Zealand operations along with another unnamed party.

Vodafone recently said that after completion of the deal, it would enter into an agreement with Vodafone New Zealand to enable it to use its brand name and specific services. The completion of the deal is still dependent on essential regulatory approvals. As of December 31, 2018, Vodafone New Zealand had nearly two million mobile customers compared to about 700 million for parent Vodafone Group.

Sources mentioned that separately, Vodafone Idea, India’s largest telecom operator, is planning to raise money through a private infrastructure investment trust of its fibre assets. To transfer its optical fibre assets to a wholly owned subsidiary named Vodafone Towers, the company is planning to seek shareholder approval.

Source Credit: https://finance.yahoo.com/news/vodafone-offloads-nz-business-brookfield-175911557.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...